UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/768,185	01/24/2001	Francis Kalush	CL000280	1938

25748 7590 07/28/2003

CELERA GENOMICS CORP.
ATTN: WAYNE MONTGOMERY, VICE PRES, INTEL PROPERTY
45 WEST GUDE DRIVE
C2-4#20
ROCKVILLE, MD 20850

EXAMINER	
MURPHY, JOSEPH F	

ART UNIT	PAPER NUMBER
1646	17

DATE MAILED: 07/28/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Applicati n N .	Applicant(s)	
	09/768,185	KALUSH ET AL.	
	Examiner	Art Unit	
	Joseph F Murphy	1646	

-- The MAILING DATE f this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *03 April 2003* .

2a)☐ This action is **FINAL**. 2b)☒ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) *18-26 and 28-40* is/are pending in the application.

4a) Of the above claim(s) *22-25,28-31 and 33-36* is/are withdrawn from consideration.

5)☒ Claim(s) *20,26,32 and 39* is/are allowed.

6)☒ Claim(s) *18-19, 21, 37-38, 40* is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11)☐ The proposed drawing correction filed on _____ is: a)☐ approved b)☐ disapproved by the Examiner.

If approved, corrected drawings are required in reply to this Office action.

12)☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____ .

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

14)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).

a) ☐ The translation of the foreign language provisional application has been received.

15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) ☐ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ .
4) ☐ Interview Summary (PTO-413) Paper No(s). _____ .
5) ☐ Notice of Informal Patent Application (PTO-152)
6) ☐ Other: .

DETAILED ACTION

Formal Matters

Claim 27 was cancelled, claims 18-21, 26 and 32 were amended and new claims 37-40 were added in Paper No. 16, 4/3/2003. Claims 18-26, 28-40 are pending. Claims 22-25, 28-31, 33-36 stand withdrawn from consideration pursuant to 37 CFR 1.142(b). Claims 18-21, 26, 32, 37-40 are under consideration.

Response to Amendment

The objection to the claims has been obviated by Applicant's amendment and is thus withdrawn.

The rejection of claims 26-27, 32 under 35 USC 112 first paragraph has been obviated by Applicant's amendment and is thus withdrawn.

The rejection of claims 26-27, 32 under 35 USC 112 second paragraph as being indefinite for recitation of the term "high stringency" has been obviated by Applicant's amendment and is thus withdrawn.

The rejection under 35 USC 102(b) has been obviated by Applicant's amendment and is thus withdrawn.

New issues are set forth below.

Claim Rejections - 35 USC § 112 first paragraph

The following is a quotation of the first paragraph of 35 U.S.C. 112:

> The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 18-19, 21, 37-38, 40 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a nucleic acid sequence of SEQ ID NO: 1, wherein the nucleotide at position 89837 is 'T' instead of 'C', does not reasonably provide enablement for a nucleic acid sequence which comprises at least 20 or 30 contiguous nucleotides of SEQ ID NO: 1, with the T to C mutation, and a nucleic acid sequence which comprises nucleotides from 89803-89998 of SEQ ID NO: 1, with the T to C mutation. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

The claims encompass a nucleic acid sequence which comprises at least 20 or 30 contiguous nucleotides of SEQ ID NO: 1, with the T to C mutation, and a nucleic acid sequence which comprises nucleotides from 89803-89998 of SEQ ID NO: 1, with the T to C mutation. The specification discloses that SEQ ID NO: 1 encodes an estrogen receptor. The art teaches that even single amino acid changes or differences in the amino acid sequence of a protein can have dramatic effects on the protein's function. It is also known in the art that a single amino acid change in a protein's sequence can drastically affect the structure of the protein and the architecture of an entire cell. For example, Voet et al. (1990) teaches that a single Glu to Val substitution in the beta subunit of hemoglobin causes the hemoglobin molecules to associate with one another in such a manner that, in homozygous individuals, erythrocytes are altered from their

normal discoid shape and assume the sickle shape characteristic of sickle-cell anemia, causing hemolytic anemia and blood flow blockages (pages 126-128, section 6-3A and page 230, column 2, first paragraph). Since the claims encompass variant nucleic acids and given the art recognized unpredictability of the effect of mutations on protein function, it would require undue experimentation to make and use the claimed invention. The Voet reference demonstrates that even single amino acid changes or differences in the amino acid sequence of a protein can have dramatic effects on the protein's function. Working examples are provided for SEQ ID NO: 1 encoding estrogen receptor beta. Given the breadth of claims 18-19, 21, 37-38, 40 in light of the predictability of the art as determined by the number of working examples, the level of skill of the artisan, and the guidance provided in the instant specification and the prior art of record, it would require undue experimentation for one of ordinary skill in the art to make and use the claimed invention.

The claims do not include a functional limitation for the claimed nucleic acids. Since detailed information regarding the structural and functional requirements of the nucleic acids encoding polypeptides are lacking, it is unpredictable as to which encoding variations, if any, meet the limitations of the claims. Furthermore, since the claims are drawn to a nucleic acid sequence which comprises at least 20 or 30 contiguous nucleotides of SEQ ID NO: 1, with the T to C mutation, and a nucleic acid sequence which comprises nucleotides from 89803-89998 of SEQ ID NO: 1, with the T to C mutation, while the claims do not recite a functional limitation for the encompassed nucleic acids encoding amino acid sequences, there is not sufficient direction as to how to use the encompassed nucleic acids encoding polypeptides which do not function as an estrogen receptor. Since no functional language is associated with the claims one

of ordinary skill in the art would not know how to use these defined sequences except in further characterization of the sequences themselves. In the instant case there are a large number of nucleic acid sequences which comprises at least 20 or 30 contiguous nucleotides of SEQ ID NO: 1, with the T to C mutation, and a nucleic acid sequence which comprises nucleotides from 89803-89998 of SEQ ID NO: 1, with the T to C mutation, however these sequences encode various unrelated proteins. Therefore, while the specification provides the necessary guidance to make the polynucleotides set forth in SEQ ID NO: 1, it does not provide the necessary guidance for one of skill in the art to use the nucleic acid sequences which do not encode an estrogen receptor.

Claims 18-19, 21, 37-38, 40 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to

reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. Applicant is directed to the Guidelines for the Examination of Patent Applications Under the 35 U.S.C. 112, ¶ 1 "Written Description" Requirement, Federal Register, Vol. 66, No. 4, pages 1099-1111, Friday January 5, 2001.

These are genus claims. The claims are drawn to a nucleic acid sequence which comprises at least 20 or 30 contiguous nucleotides of SEQ ID NO: 1, with the T to C mutation, and a nucleic acid sequence which comprises nucleotides from 89803-89998 of SEQ ID NO: 1, with the T to C mutation. The written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant identifying characteristics, i.e. structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between structure and function structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus. In the instant case, the specification fails to describe more than a single species of the genus, the claims do not include a functional limitation for the claimed nucleic acids, and because one of skill in the art could not be expected to predict the biological activity of the sequence variants encompassed by the claims, the specification fails to provide sufficient descriptive information, such as definitive structural or functional features of the claimed genus of polynucleotides. There is no description of the conserved regions which are critical to the structure and function of the genus claimed. There is no description of the sites at which variability may be tolerated and there is no information regarding the relation of structure to

function. Structural features that could distinguish the compounds in the genus from other seven transmembrane region compounds are missing from the disclosure. Furthermore, the prior art does not provide compensatory structural or correlative teachings sufficient to enable one of skill to isolate and identify the polynucleotides encompassed: there is no guidance in the art as to what the defining characteristics of the peptides might be. Thus, applicant was not in possession of the claimed genus.

Conclusion

Claims 20, 26, 32, 39 are allowable.

Claims 18-19, 21, 37-38, 40 are rejected.

Advisory Information

. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joseph F. Murphy whose telephone number is 703-305-7245. The examiner can normally be reached on M-F 7:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached on 703-308-6564. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-308-0294 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196

Joseph F. Murphy, Ph. D.
Patent Examiner
Art Unit 1646
July 17, 2003

YVONNE EYLER, PH.D
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600